Tags

Type your tag names separated by a space and hit enter

Middle ear adenomatous neuroendocrine tumors: suggestion for surgical strategy.
Braz J Otorhinolaryngol. 2020 Jun 15 [Online ahead of print]BJ

Abstract

INTRODUCTION

Middle ear adenomatous neuroendocrine tumors are extremely rare neoplasms with epithelial and neuroendocrine differentiation, accounting for fewer than 2% of all middle and inner ear tumors. Universal standard surgical procedures for different stages of these tumors remain elusive due to the limitation of the small number of case reports or investigations.

OBJECTIVE(S)

This study intends to investigate proper surgical strategies for patients with middle ear adenomatous neuroendocrine tumors.

METHODS

Six patients with middle ear adenomatous neuroendocrine tumors who were treated at the Second Affiliated Hospital of Nanchang University (Nanchang, China) and the Eye, Ear, Nose, and Throat Hospital of Fudan University (Shanghai, China) respectively. Clinical characteristics and management strategies of patients were reviewed. The mean follow-up time was 63.7 months (range, 13-153 months). All the information was collected from medical records and prognosis postoperatively.

RESULTS

Three patients underwent canal wall-up tympanomastoidectomy, including one patient with recurrence who underwent a previous tympanotomy; the other three patients underwent lateral temporal bone resection All of these patients were followed up with no evidence of recurrence or metastasis. Patients underwent canal wall-up surgery treatment accompanied with hearing function preservation measurements during follow-up periods.

CONCLUSIONS

Complete surgical resection provided good results for patients with middle ear adenomatous neuroendocrine tumors. The ossicular chain should be removed. Because of the propensity for local recurrence and invasiveness, as well as regional or distant metastasis of these tumors, it is necessary to schedule long-term follow-up and an observation plan postoperatively.

Authors+Show Affiliations

The Second Affiliated Hospital of Nanchang University, Department of Otolaryngology Head and Neck Surgery, Nanchang, China; Jiangxi Biomedical Engineering Research Center for Auditory Research, Nanchang, China.The Second Affiliated Hospital of Nanchang University, Department of Otolaryngology Head and Neck Surgery, Nanchang, China; Jiangxi Biomedical Engineering Research Center for Auditory Research, Nanchang, China.Fudan University, Eye and Ear, Nose, and Throat Hospital, Department of Otology and Skull Base Surgery, Shanghai, China. Electronic address: cfdai66@163.com.The Second Affiliated Hospital of Nanchang University, Department of Otolaryngology Head and Neck Surgery, Nanchang, China; Jiangxi Biomedical Engineering Research Center for Auditory Research, Nanchang, China. Electronic address: liuyuehuiclark@21cn.com.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32605830

Citation

Xie, Bingbin, et al. "Middle Ear Adenomatous Neuroendocrine Tumors: Suggestion for Surgical Strategy." Brazilian Journal of Otorhinolaryngology, 2020.
Xie B, Zhang S, Dai C, et al. Middle ear adenomatous neuroendocrine tumors: suggestion for surgical strategy. Braz J Otorhinolaryngol. 2020.
Xie, B., Zhang, S., Dai, C., & Liu, Y. (2020). Middle ear adenomatous neuroendocrine tumors: suggestion for surgical strategy. Brazilian Journal of Otorhinolaryngology. https://doi.org/10.1016/j.bjorl.2020.05.011
Xie B, et al. Middle Ear Adenomatous Neuroendocrine Tumors: Suggestion for Surgical Strategy. Braz J Otorhinolaryngol. 2020 Jun 15; PubMed PMID: 32605830.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Middle ear adenomatous neuroendocrine tumors: suggestion for surgical strategy. AU - Xie,Bingbin, AU - Zhang,Shaorong, AU - Dai,Chunfu, AU - Liu,Yuehui, Y1 - 2020/06/15/ PY - 2020/01/31/received PY - 2020/03/24/revised PY - 2020/05/06/accepted PY - 2020/7/2/entrez KW - Adenomas KW - Carcinoid tumor KW - Crânio KW - Ear, Middle KW - Orelha média KW - Osso temporal KW - Skull KW - Temporal bone KW - Tumor carcinoide JF - Brazilian journal of otorhinolaryngology JO - Braz J Otorhinolaryngol N2 - INTRODUCTION: Middle ear adenomatous neuroendocrine tumors are extremely rare neoplasms with epithelial and neuroendocrine differentiation, accounting for fewer than 2% of all middle and inner ear tumors. Universal standard surgical procedures for different stages of these tumors remain elusive due to the limitation of the small number of case reports or investigations. OBJECTIVE(S): This study intends to investigate proper surgical strategies for patients with middle ear adenomatous neuroendocrine tumors. METHODS: Six patients with middle ear adenomatous neuroendocrine tumors who were treated at the Second Affiliated Hospital of Nanchang University (Nanchang, China) and the Eye, Ear, Nose, and Throat Hospital of Fudan University (Shanghai, China) respectively. Clinical characteristics and management strategies of patients were reviewed. The mean follow-up time was 63.7 months (range, 13-153 months). All the information was collected from medical records and prognosis postoperatively. RESULTS: Three patients underwent canal wall-up tympanomastoidectomy, including one patient with recurrence who underwent a previous tympanotomy; the other three patients underwent lateral temporal bone resection All of these patients were followed up with no evidence of recurrence or metastasis. Patients underwent canal wall-up surgery treatment accompanied with hearing function preservation measurements during follow-up periods. CONCLUSIONS: Complete surgical resection provided good results for patients with middle ear adenomatous neuroendocrine tumors. The ossicular chain should be removed. Because of the propensity for local recurrence and invasiveness, as well as regional or distant metastasis of these tumors, it is necessary to schedule long-term follow-up and an observation plan postoperatively. SN - 1808-8686 UR - https://www.unboundmedicine.com/medline/citation/32605830/Middle_ear_adenomatous_neuroendocrine_tumors:_suggestion_for_surgical_strategy L2 - https://linkinghub.elsevier.com/retrieve/pii/S1808-8694(20)30069-0 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.